You are here: Industry Insights > cancer

News List

Obesity both feeds tumors and helps immunotherapy kill cancer worldpharmanews
November 15, 2018
A groundbreaking new study by UC Davis researchers has uncovered why obesity both fuels cancer growth and allows blockbuster new immunotherapies to work better against those same tumors. The paradoxical findings, published today in Nature Medicine, give c
The top 10 cancer drug makers of 2024 fiercepharma
November 15, 2018
At first glance, the list of cancer drug makers predicted to head the field by 2024 may not look so different from the list of top-selling cancer drug makers in 2017.
Planning and implementing biomarker testing for immuno-oncology trials fiercepharma
November 15, 2018
Foundations laid by important cancer biology and immunology research throughout the last decades have led to game-changing clinical breakthroughs in the field of immuno-oncology
Genomic profiling offers hope for rare cancer treatments pharmaceutical-technology
November 14, 2018
A clinical trial led by Walter and Eliza Hall Institute of Medical Research in Australia has demonstrated that genomic profiling could help match rare cancer patients with appropriate treatments.
As Novartis' other cancer launches struggle, Lutathera gets off to flying start fiercepharma
November 11, 2018
Novartis has stumbled with a couple of its recent cancer launches, namely the complicated CAR-T rollout for Kymriah and come-from-behind Kisqali debut. But not so with Lutathera.
As Novartis' other cancer launches struggle, Lutathera gets off to flying start fiercepharma
November 11, 2018
Novartis has stumbled with a couple of its recent cancer launches, namely the complicated CAR-T rollout for Kymriah and come-from-behind Kisqali debut. But not so with Lutathera.
FDA Approves Udenyca，Udenyca is Coherus’ first drug to receive FDA or EC approval americanpharmaceuticalreviewpharmaceutical-technol
November 10, 2018
Coherus BioSciences announced the U.S. Food and Drug Administration (FDA) has approved Udenyca (pegfilgrastim-cbqv), the first pegfilgrastim biosimilar approved by both the FDA and the European Commission (EC) for patients with cancer receiving myelosuppr
Gap in research means millions living with long-term consequences of cancer worldpharmanews
November 10, 2018
This growing population report side-effects that seriously affect their quality of life, but a combination of a shortage of funding, a lack of clear direction and relatively few researchers with expertise in this area have left a gap in cancer research.
Tumour immune cells could aid cancer therapies worldpharmanew
November 10, 2018
A pioneering technique designed to spot differences between immune cells in tumours could speed the development of cancer treatments, research suggests. Scientists say the approach could be used to help doctors choose the best treatments for individual pa
Gilead Sciences and Tango Therapeutics Announce Strategic Collaboration to Develop Next-Generation Targeted Immuno-Oncology Therapies pharmafocusasia
November 05, 2018
Gilead Sciences, Inc and Tango Therapeutics, Inc., a company focused on the discovery and development of novel cancer therapies...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 88 89 Next page